Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Nature Communications
|
February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
NPJ Genomic Medicine
|
April 10, 2026
Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling
Junko Tsuji, Micah Rickles-Young, Justin Abreu, et al.
Blood
|
March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q
Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Christopher J Gibson, Haesook T Kim, Lin Zhao, et al.
Nature Communications
|
April 8, 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Omar Nadeem, Michelle P Aranha, Robert A Redd, et al.
Nature Cancer
|
August 8, 2025
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
Elizabeth D Lightbody, Romanos Sklavenitis-Pistofidis, Ting Wu, et al.
The Lancet. Oncology
|
January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network
Zexian Zeng, Jingxin Fu, Carrie Cibulskis, et al.
Nature Neuroscience
|
November 26, 2015
The PsychENCODE project
, Schahram Akbarian, Chunyu Liu, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Nature Communications
|
February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
NPJ Genomic Medicine
|
April 10, 2026
Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling
Junko Tsuji, Micah Rickles-Young, Justin Abreu, et al.
Blood
|
March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q
Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Christopher J Gibson, Haesook T Kim, Lin Zhao, et al.
Nature Communications
|
April 8, 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Omar Nadeem, Michelle P Aranha, Robert A Redd, et al.
Nature Cancer
|
August 8, 2025
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
Elizabeth D Lightbody, Romanos Sklavenitis-Pistofidis, Ting Wu, et al.
The Lancet. Oncology
|
January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network
Zexian Zeng, Jingxin Fu, Carrie Cibulskis, et al.
Nature Neuroscience
|
November 26, 2015
The PsychENCODE project
, Schahram Akbarian, Chunyu Liu, et al.
Page
of 3